 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- This article will reflect on the compensation paid to Yatomi-Clarke Lee who has
  served as CEO of Prescient Therapeutics Limited (ASX:PTX) since 2016. This analysis
  will also assess whether PrescientRead More...


How Much Did Prescient Therapeutics' (ASX:PTX) CEO Pocket Last Year?

---
- Legendary fund manager Li Lu (who Charlie Munger backed) once said, The biggest
  investment risk is not the volatility of prices, but whether you will suffer a permanent
  loss ofRead More...


Petrotx - Limited Partnership (TLV:PTX) Has Debt But No Earnings; Should You Worry?

---
- Pharmaceutical firm Pernix Therapeutics Holdings Inc., which makes painkiller Zohydro
  and other medications, has filed for bankruptcy protection after drug sales to consumers
  fell below expectations.
- The Morristown, N.J., company filed for chapter 11 protection on Monday after laying
  off 89 workers.
- Roughly 30 workers remain at the company, which plans to look for buyers.


Drug Maker Pernix Therapeutics Files for Bankruptcy, Blaming Competition From Generics

---
- |-
  Transaction that includes the sale of substantially all of Pernix’s assets to be valued at $75.6 million



  Pernix intends to continue to operate with no disruption to the availability of Pernix products and patient support services

  MORRISTOWN, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a holding company that owns several subsidiaries, including specialty pharmaceutical companies, today announced that it has entered into an Asset Purchase Agreement with certain funds managed by Highbridge Capital Management, LLC (collectively “Highbridge”).
- "\"We believe that pursuing this restructuring and sale process is in the best interest
  of the Company and our stakeholders,” said John Sedor, Chief Executive Officer of
  Pernix."
- In addition, any statements related to Pernix’s plans to sell all of its assets
  pursuant to Chapter 11 of the U.S. Bankruptcy Code; Pernix’s intention to continue
  operations while Pernix works to complete its sale and restructuring process; Pernix’s
  intended use of the proceeds from the DIP financing; Pernix’s belief that the restructuring
  and sale process will be in the best interest of the Company and its stakeholders;
  the continued uninterrupted access to the Company’s medications and patient support
  services during the Chapter 11 proceedings; Pernix’s goal to conclude the sale process
  by May 2019 and other statements regarding the Company’s strategy and future operations,
  performance and prospects are forward-looking statements.
- 'Such plans, expectations and statements are as to future events and are not to
  be viewed as facts, and reflect various assumptions of management of the Company
  and are subject to significant business, financial, economic, operating, competitive,
  litigation and other risks and uncertainties and contingencies (many of which are
  difficult to predict and beyond the control of the Company) that could cause actual
  results to differ materially from the statements included herein, including, without
  limitation: the potential adverse impact of the Chapter 11 filings on Pernix’s liquidity
  and results of operations; changes in Pernix’s ability to meet its financial obligations
  during the Chapter 11 process and to maintain contracts that are critical to its
  operations; the outcome and timing of the Chapter 11 process and the proposed auction
  and asset sale; the effect of the Chapter 11 filings and proposed asset sale on
  Pernix’s relationships with vendors, regulatory authorities, employees and other
  third parties; possible proceedings that may be brought by third parties in connection
  with the Chapter 11 process or the proposed asset sale; uncertainty regarding obtaining
  bankruptcy court approval of a sale of Pernix’s assets or other conditions to the
  proposed asset sale; and the timing or amount of any distributions, if any, to the
  company’s stakeholders.'
- Investors should note that many factors, including those more fully described in
  Pernix’s filings with the Securities and Exchange Commission (“SEC”) (including,
  but not limited to, its Annual Report on Form 10-K for the year ended December 31,
  2017 and its Quarterly Report on Form 10-Q for the Quarterly Period ended September
  30, 2018 and other filings with the SEC), could affect the Company’s future financial
  results and could cause actual results to differ materially from those expressed
  in forward-looking statements, such as those contained in this press release.


Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management

---
- Every investor in Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) should be aware
  of the most powerful shareholder groups.
- With a market capitalization of US$26m, Pernix Therapeutics Holdings is a small
  cap stock, so it might not be well known by many institutional investors.
- Pernix Therapeutics Holdings already has institutions on the share registry.
- Our data indicates that hedge funds own 7.4% of Pernix Therapeutics Holdings.
- Our data suggests that insiders own under 1% of Pernix Therapeutics Holdings, Inc.
  in their own names.


Could The Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Ownership Structure Tell Us Something Useful?

---
- NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Traders News Source, a leading independent
  equity research and corporate access firm focused on small and mid-cap public companies
  is issuing a comprehensive report on Pernix Therapeutics Holdings, Inc., (PTX) Pernix
  is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business
  focused on acquiring and commercializing prescription drugs, primarily for the U.S.
  market.
- During the third quarter, Contrave remained the leading prescription weight loss
  brand in the United States, and the company is currently exploring a number of initiatives
  to enhance the value of the brand globally.
- |-
  This full report explores the initiatives for a turnaround, revenue and progress READMORE

  Copy and paste to your browser may be required to view the report -  the last quarter, the company' primary asset - Zohydro ER generated its third consecutive quarter of year-over-year net revenue growth in the third quarter.
- Pernix is extremely encouraged with the initial results from Contrave, which is
  the market-leading branded weight loss prescription drug.
- |-
  The full research report available with no obligation covers currently approved products, respective revenues and more READ MORE

  Copy and paste to your browser may be required to view the report -  document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only.


Analyst Reports Pernix Therapeutics Holdings, Inc. is Laying the Foundation for a Turnaround

---
- |-
  All markets data located on FT.com is subject to the FT Terms & Conditions

  All content on FT.com is for your general information and use only and is not intended to address your particular requirements.
- In particular, the content does not constitute any form of advice, recommendation,
  representation, endorsement or arrangement by FT and is not intended to be relied
  upon by users in making (or refraining from making) any specific investment or other
  decisions.
- Any information that you receive via FT.com is at best delayed intraday data and
  not "real time".
- Share price information may be rounded up/down and therefore not entirely accurate.
- FT is not responsible for any use of content by you outside its scope as stated
  in the FT Terms & Conditions


Pernix Therapeutics Holdings Inc, PTX:NMQ forecasts - FT.com

---
- Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J., June
  16, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a
  specialty pharmaceutical company, today announced positive final results from a
  Phase IV Study assessing the effects of nighttime administration of insomnia treatments,
  Silenor ® 6 mg and zolpidem 10 mg, as well as placebo, on arousability, gait, balance,
  and cognitive performance, after going to sleep, in healthy male volunteers.
- The study assessed the effects of a single dose of Silenor 6 mg compared with matching
  placebo and a single dose of zolpidem 10 mg compared to its matching placebo at
  the respective Tmax (time the maximum serum concentrations are observed) in normal
  healthy adult male volunteers (n=52).
- The results of the study demonstrated that Silenor 6 mg was statistically superior
  to zolpidem 10 mg on the measures studied - arousability, gait, balance, and memory.
- The results also indicated that subjects taking Silenor 6 mg did not have impairment
  on arousability, gait, balance, and cognitive performance, and were comparable to
  placebo.
- Further, in addition to Silenor 6 mg, both placebo groups were also statistically
  superior to zolpidem on the measures evaluated, indicating that zolpidem subjects
  had statistically significant difficulty in waking up, with walking and balance
  and with memory.


Pernix Therapeutics Announces Positive Phase IV Results Of Silenor® Vs. Zolpidem Head-to-Head Arousability Study

---
- On the call today are Graham Miao, President and Chief Financial Officer; George
  Jones, Vice President of Sales and Marketing; and Angus Smith, Vice President, Business
  Development and Strategic Planning of Pernix Therapeutics.
- We look forward to working with the talented and dedicated Pernix team to create
  new growth opportunities and move the Company forward.
- Just a few weeks ago, we announced a reorganization of the Company's senior management
  team intended to improve Pernix's efficiency, drive profitability, and position
  the Company for future growth.
- Since John joined as CEO, we have worked hard with our team to undertake an in-depth
  review of Pernix's products, sales trends, productivity of our sales and marketing
  efforts, internal cost structure, and personnel.
- Moving to our pain salesforce, we expect the optimization will enable us to increase
  our coverage of Zohydro ER with BeadTek prescriptions by 19%, while shifting our
  focus to the highest-value pain specialists, with whom we have significant opportunity
  to accelerate our brand growth.


Edited Transcript of PTX earnings conference call or presentation 11-Aug-16 8:30pm GMT

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. It distributes products through the following brands: Treximet, Silenor, and Zohydro ER with BeadTek. The company was founded in 1996 and is headquartered in Morristown, NJ.

Watchers	16,762
52-Wk Low	$0.017
52-Wk High	$2.65

Market Cap	$403,400.00
Volume (M)	16,105.00
52-Wk High	$2.65
52-Wk Low	$0.017

PTX Pernix Therapeutics Holdings, Inc.

About

Feed

News

Fundamentals